Analysis Of The Effect Of Crossover From Placebo (Pbo) To Darolutamide (Daro) On Overall Survival (Os) Benefit In The Aramis Trial

Niara Oliveira,Neal Shore,Karim Fizazi,Teuvo Tammela,Murilo Luz,Manuel Philco Salas,Paul Ouellette Jr,Sergio Lago, Diogo Bastos,G. Kenneth Jansz,Flavio Mavignier Carcano,Livia Andrade,Marc Pliskin,Nicolas Lazaretti,Larissa De Arruda,Jose Jaime Correa,Christian Kappeler,Toni Sarapohja,Matthew Smith

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览12

暂无评分

摘要

240Background: DARO is a structurally distinct androgen receptor inhibitor approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) based on significantly prolonge...

查看译文

关键词

Prostate cancer,Darolutamide,Androgen receptor,Placebo,Oncology,Medicine,Internal medicine,Overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要